Clinical Trial News and Research

RSS

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

Accovion establishes new subsidiary in the UK

As a European full-service Clinical Research Organization, Accovion supports local and global projects of all types and phases for the Pharmaceutical, Biotechnology and Medical Device industries.

20 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Medical food resolves metabolic syndrome and cardiovascular risk factors

Researchers at the University of Florida and Metagenics Inc. today announced that a program consisting of a breakthrough medical food combined with a low-glycemic, Mediterranean-style diet is almost twice as effective as one of the best diets alone for lowering risk factors for cardiovascular disease, the leading cause of death in the U.S.

19 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Omeros Corporation today announced that it is advancing two of its product candidates from its PharmacoSurgery platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs.

19 May 2011

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

This year HIV Vaccine Awareness Day comes at the dawn of a true prevention revolution that could finally turn the tide of the AIDS epidemic. AIDS vaccine research is a critical part of that revolution and on this day AVAC calls on donors, policy makers and others to strengthen support for AIDS vaccine research.

19 May 2011

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.

19 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Aspirin, simvastatin not effective in combating pulmonary artery hypertension

Despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension (PAH), according to a National Institutes of Health (NIH)-funded study conducted at four U.S. medical centers. This was the first NIH-funded randomized clinical trial (RCT) in PAH.

19 May 2011

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.

19 May 2011

New insight into skin hardening syndromes

Researchers from Boston University School of Medicine have discovered new details about the underlying mechanisms of skin hardening syndromes.

18 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Clinical Trial News and Research

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Accovion establishes new subsidiary in the UK

RTOG reports on largest trial for newly diagnosed glioblastoma

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Medical food resolves metabolic syndrome and cardiovascular risk factors

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Aspirin, simvastatin not effective in combating pulmonary artery hypertension

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

New insight into skin hardening syndromes

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer